Budesonide With Intratracheal Surfactants in Extremely Preterm Infants
Status:
Unknown status
Trial end date:
2021-01-15
Target enrollment:
Participant gender:
Summary
This is a phase I/II trial in preterm infants aimed at identifying the optimal dose of
budesonide with bovine lipid extract surfactant as vehicle for intratracheal administration.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Manitoba
Collaborators:
BLES Biochemicals Inc. Health Sciences Centre, Winnipeg, Manitoba Manitoba Institute of Child Health St. Boniface General Hospital Research Centre St. Boniface Hospital University of Utah Winnipeg Rh Institute Foundation Inc.